A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86440
Title:
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Authors:
Crawley, C R; Foran, J M; Gupta, R K; Rohatiner, A Z; Summers, K; Matthews, J; Micallef, I N; Radford, John A ( 0000-0001-7898-2786 ) ; Johnson, Stephen A; Johnson, Peter W; Sweetenham, J W; Lister, T Andrew
Abstract:
BACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.
Affiliation:
Department of Medical Oncology, St. Bartholomew's Hospital, London, UK.
Citation:
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. 2000, 11 (7):861-5 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Jul-2000
URI:
http://hdl.handle.net/10541/86440
PubMed ID:
10997815
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCrawley, C Ren
dc.contributor.authorForan, J Men
dc.contributor.authorGupta, R Ken
dc.contributor.authorRohatiner, A Zen
dc.contributor.authorSummers, Ken
dc.contributor.authorMatthews, Jen
dc.contributor.authorMicallef, I Nen
dc.contributor.authorRadford, John Aen
dc.contributor.authorJohnson, Stephen Aen
dc.contributor.authorJohnson, Peter Wen
dc.contributor.authorSweetenham, J Wen
dc.contributor.authorLister, T Andrewen
dc.date.accessioned2009-11-19T10:07:21Z-
dc.date.available2009-11-19T10:07:21Z-
dc.date.issued2000-07-
dc.identifier.citationA phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. 2000, 11 (7):861-5 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid10997815-
dc.identifier.urihttp://hdl.handle.net/10541/86440-
dc.description.abstractBACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.en
dc.language.isoenen
dc.subjectCancer DNAen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshDNA, Neoplasm-
dc.subject.meshDexamethasone-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMitoxantrone-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshRecurrence-
dc.subject.meshTreatment Outcome-
dc.subject.meshVidarabine-
dc.titleA phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, St. Bartholomew's Hospital, London, UK.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.